Marilu Henner Encourages Tough Talks on Bladder Cancer

May 17, 2017
by Stephanie Chisolm

For Bladder Cancer Awareness Month, BCAN and actress Marilu Henner have partnered with Genentech, a member of the Roche group, to share her personal story and help people navigate challenging – but necessary – conversations about bladder cancer. Marilu knows firsthand the importance of these discussions. In 2003, she and her now husband Michael Brown were on vacation when she learned he had blood in his urine. Michael had told his urologist about this symptom before Marilu knew about it, but the urologist told him it was nothing to worry about. “I am incredibly dedicated to my health and the…

Read More...

New Guidelines for Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer!

May 12, 2017
by Stephanie Chisolm

For the first time for any type of malignancy, the American Urological Association (AUA), the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) have formulated an evidence-based guideline for the treatment of non-metastatic muscle-invasive bladder cancer. BCAN Co-Founder, Diane Z. Quale represented patients on the panel of experts that recognized the importance of multidisciplinary collaborative efforts that take into account survival and quality-of-life (QOL) concerns, as they developed the guidelines. Read the new guidelines below: AUA/ASCO/ASTRO/SUO Guideline Share this page:

Read More...

FDA Approves PD-L1 Inhibitor Avelumab (BAVENCIO) for Bladder Cancer

May 9, 2017
by Alejandra Spangler

The PD-L1 inhibitor avelumab (BAVENCIO) has been granted accelerated approval by the Food and Drug Administration. This treatment by Pfizer, Inc. and EMD Serono is targeted to patients with locally advanced or metastatic urothelial carcinoma with disease progression during or following platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. “Until recently, there had been limited innovation in urothelial carcinoma, and this approval gives us another treatment to help battle this aggressive disease.” – Andrea Apolo, MD, medical oncologist at the National Cancer Institute and member of our Scientific Advisory Board Click below to read EMD Serono’s Press Release…

Read More...

FDA accelerates approval of IMFINZI (durvalumab)

May 3, 2017
by Alejandra Spangler

The Food and Drug Administration grants an accelerated approval of IMFINZI (durvalumab), a breakthrough therapy for previously treated advanced bladder cancer patients. This therapy focuses on identifying and attacking cancer cells by restoring the immune system.  This is AstraZeneca’s first approved Immuno-Oncology (IO) therapy.   “We are excited to offer Imfinzi as a breakthrough therapy for patients with locally-advanced or metastatic bladder cancer. Imfinzi is the cornerstone of our extensive Immuno-Oncology programme, in development across many tumour types, as monotherapy and in combination. This first approval for Imfinzi is an important milestone in our return to growth and brings us another step closer…

Read More...

TURBT Important Tool

April 20, 2017
by Stephanie Chisolm

URO Today  article notes that the precise and thorough resection (TURBT) of all existing tumors remains a critical factor influencing bladder cancer patient outcomes. It can not only reduce the incidence of under-staging, but also can provide the optimal setting for adjuvant therapy (additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back.) Enhanced cystoscopy has a critical role to play in helping urologists in this area, as recommended by the updated AUA/SUO guidelines on NMIBC. Read the article by BCAN Scientific Advisory Board member Ashish Kamat, MD and Kamal Pohar, MD here. Share this page:

Read More...

BCAN Launches My Bladder Cancer Story

February 21, 2017
by Stephanie Chisolm

This year, over 79,000 people will be diagnosed with bladder cancer. BCAN understands that there are real people behind this number. Our ‘My Bladder Cancer Story’ Campaign presents stories to raise awareness and call attention to the lives and daily experiences of bladder cancer patients and families nationwide. Read the stories            Share your Story Share this page:

Read More...

BMS Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

February 3, 2017
by Stephanie Chisolm

BCAN applauds the U.S. Food and Drug Administration (FDA) for approving Opdivo for use for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. “Although bladder cancer is the 5th most commonly diagnosed cancer in the United States, it is only recently that we are starting to see new treatments being approved to help patients with this disease,” according to Andrea Maddox-Smith, CEO of BCAN.  “The FDA’s approval of Opdivo offers a much-needed treatment option for the…

Read More...

BCAN Launches Winter Webinar Series!

December 13, 2016
by Stephanie Chisolm

Wondering what to do on chilly winter nights this January and February? Wish you knew more about bladder cancer? Sign up now for our Bladder Cancer 2017 Winter Webinar Series. We bring the experts to you! You don’t even have to shovel the walk or leave your home to join us for these free Patient Insight Webinars. Make some hot chocolate, grab a blanket and your computer. Leading bladder cancer experts will answer your questions about pathology, bladder removal, and sexuality. To see the full details and to register Click here   Share this page:

Read More...

Dr. Neal Shore appointed to BCAN Board of Directors

November 28, 2016
by Stephanie Chisolm

Bladder Cancer Advocacy Network is pleased to announce the appointment of Neal D. Shore, MD, to its Board of Directors. Dr. Shore is an internationally recognized expert and researcher in systemic therapies for advanced urologic cancers. The medical director of the Carolina Urologic Research Center, he practices with Atlantic Urology Clinics in Myrtle Beach, S.C.  Dr. Shore brings extensive experience and expertise to the BCAN Board of Directors. He has conducted more than 250 clinical trials, focusing mainly on genitourinary oncology and has more than 125 peer-reviewed publications and numerous book chapters. He serves on several industry advisory boards; he is the…

Read More...